Liverscan®: Ultrasound Device for Liver Fibrosis and Steatosis Assessment

Lead  Prof. ZHENG Yongping

Department of Biomedical Engineering | Research Institute for Smart Ageing

Fatty liver, with global prevalence of about 30%, can lead to fibrosis, and, if not treated, may progress to severe liver diseases such as cirrhosis and even cancer. Prof. Zheng Yongping and his team have researched image-guided ultrasound transientelastography, and developed Liverscan^® by combining transient elastography diagnostic technology with a real‑time ultrasound image‑guided system and AI-empowered data processing.

Liverscan^® is a palm-sized, wireless ultrasound device for non-invasive assessment of liver steatosis and fibrosis. It performs assessment three to five times faster than conventional devices at only a fraction of the conventional cost. Nearly a hundred sets of Liverscan^® have been installed in different countries and served over 60,000 people for screening, diagnosis, and follow-up check.

Liverscan^® has been successfully commercialised through a University start‑up, generating HK$9million in revenue and attracting further investment of over HK$35million.